Last reviewed · How we verify
JNJ-64042056 — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
JNJ-64042056 (JNJ-64042056) — Janssen Pharmaceutica N.V., Belgium.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| JNJ-64042056 TARGET | JNJ-64042056 | Janssen Pharmaceutica N.V., Belgium | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- JNJ-64042056 CI watch — RSS
- JNJ-64042056 CI watch — Atom
- JNJ-64042056 CI watch — JSON
- JNJ-64042056 alone — RSS
Cite this brief
Drug Landscape (2026). JNJ-64042056 — Competitive Intelligence Brief. https://druglandscape.com/ci/jnj-64042056. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab